|[December 17, 2013]
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Catalyst Pharmaceutical Partners, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 24, 2013
NEW YORK --(Business Wire)--
Levi & Korsinsky announces that a class action lawsuit has been
commenced in the United States District Court for the Southern District
of Florida on behalf of investors who purchased Catalyst Pharmaceutical
Partners, Inc. ("Catalyst Pharmaceutical" or the "Company") (NasdaqCM:
CPRX) common stock between October 31, 2012 and October 18, 2013.
For more information, click here: http://zlk.9nl.com/catalyst-pharmaceutical-partners-cprx/.
The Complaint alleges that the Company made materially false and
misleading tatements and/or failed to disclose materially adverse facts
during the Class Period. In particular it is alleged that Catalyst
Pharmaceutical failed to disclose that one of its competitors has
already been manufacturing a drug biologically equivalent to the
Company's drug Firedapse, and that this competitor was providing the
drugs to patients to treat Lambert-Eaton (News - Alert) Myasthenic Syndrome (LEMS) free
of charge, through a compassionate use program.
If you suffered a loss in Catalyst you have until December 24, 2013 to
request that the Court appoint you as lead plaintiff. Your ability to
share in any recovery doesn't require that you serve as a lead
plaintiff. To obtain additional information, contact Joseph E. Levi,
Esq. either via email at firstname.lastname@example.org
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/catalyst-pharmaceutical-partners-cprx/.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, Connecticut, and Washington D.C. The firm has extensive
expertise in prosecuting securities litigation involving financial
fraud, representing investors throughout the nation in securities and
shareholder lawsuits. Attorney advertising. Prior results do not
guarantee similar outcomes.
[ Back To Technology News's Homepage ]